Table 2. High-risk (HR) HPV positivity overall and for types 16 and 18 for different tests (ordered by overall high-risk HPV positivity).
| Test | Number tested | Number adequate result | Positive (%) | HPV 16 positive (%) | HPV 18 positive (%) | Other HR HPV positive (%) |
|---|---|---|---|---|---|---|
| BD HPV |
5998 |
5965 |
970 (16.3) |
168 (2.8) |
71 (1.2) |
834 (14.0) |
| Roche Cobas |
5986 |
5979 |
959 (16.0) |
211 (3.5) |
86 (1.4) |
801 (13.4) |
| Qiagen Hybrid Capture 2 |
5984 |
5984 |
906 (15.1) |
— |
— |
— |
| Abbott RealTime High Risk HPV |
5994 |
5990 |
801 (13.4) |
180 (3.0) |
70 (1.2) |
634 (10.6) |
| Gen-Probe APTIMA |
6000 |
5995 |
620 (10.3) |
128 (2.1) |
63 (1.1)a |
— |
| NorChip PreTect HPV-Proofer | 5969 | 5747b | 297 (5.2) | 116 (2.0) c | 51 (0.9) c | 139 (2.4)d |
Abbreviations: HPV=human papillomavirus; HR=high risk.
a
Tested HPV 18/45 combined.
b
n=76 U1A mRNA not detected, n=132 testing failed for technical reasons, n=10 failed quality control, n=4 low U1A mRNA (indeterminate result).
c
Samples were excluded if the overall result was inadequate.
d
Includes only types 31, 33 and 45.